These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1071404)

  • 1. Angiotensin II blockade in patients with essential hypertension.
    MacGregor GA; Dawes PM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):53-4. PubMed ID: 1071404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II blockade in normal subjects and essential hypertensive patients.
    MacGregor GA; Dawes PM
    Clin Sci Mol Med Suppl; 1976 Dec; 3():193s-196s. PubMed ID: 1071606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of saralasin, an angiotensin II antagonist, on blood pressure and the renin-angiotensin-aldosterone system in normal and hypertensive subjects.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):48-52. PubMed ID: 1071403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 1-sar-8-ala-angiotensin II on arterial pressure, renin and aldosterone in hypertension.
    Fagard R; Lijnen P; Amery A; Reybrouck T
    Contrib Nephrol; 1978; 11():175-8. PubMed ID: 699588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects.
    Anderson GH; Streeten DH; Dalakos TG
    Circ Res; 1977 Mar; 40(3):243-50. PubMed ID: 837471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance.
    Brunner HR; Gavras H; Ribeiro AB; Posternak L
    Prog Biochem Pharmacol; 1976; 12():145-62. PubMed ID: 1019161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.
    Case DB; Wallace JM; Keim HJ; Weber MA; Drayer JI; White RP; Sealey JE; Laragh JH
    Am J Med; 1976 Nov; 61(5):790-6. PubMed ID: 185903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II blockade before and after marked sodium depletion in patients with hypertension.
    Van Hoogdalem P; Donker AJ; Leenen FH
    Clin Sci Mol Med; 1978 Jan; 54(1):75-83. PubMed ID: 620496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.
    Case DB; Wallace JM; Keim HJ; Sealey JE; Laragh JH
    Am J Med; 1976 May; 60(6):825-36. PubMed ID: 1020762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the angiotensin II antagonist 1-sar-8-ala-angiotensin II in hypertension in man.
    Fagard R; Amery A; Lijnen P; Reybrouck T
    Eur J Clin Invest; 1977 Dec; 7(6):473-9. PubMed ID: 415868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemodynamics, renin and aldosterone following angiotensin II blockade and sodium chloride deficiency in hypertensive subjects].
    Beyer J; Liebau G; Steiner B; Schick K; Hayduk K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():212-3. PubMed ID: 613577
    [No Abstract]   [Full Text] [Related]  

  • 13. [Saralasin-induced changes of blood pressure, renin and aldosterone in essential and renal hypertension (author's transl)].
    Beyer J; Liebau G; Steiner B; Hayduk K
    Klin Wochenschr; 1978 Sep; 56(17):859-64. PubMed ID: 713415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist and antagonist effects of Sar1-ala8--angiotensin II in salt-loaded and salt-depleted normal man.
    MacGregor GA; Dawes PM
    Br J Clin Pharmacol; 1976 Jun; 3(3):483-7. PubMed ID: 973974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II blockade in patients with essential hypertension.
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):61-3. PubMed ID: 1071407
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hemodynamic changes after angiotensin II blockade by saralasin (author's transl)].
    Liebau G; Beyer J; Larbig D; Schick K; Sekanina G; Hayduk K
    Klin Wochenschr; 1977 Jul; 55(13):647-9. PubMed ID: 19645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to saralasin and angiotensin's role in essential and renal hypertension.
    Hollenberg NK; Williams GH; Adams DF; Moore T; Brown C; Borucki LJ; Leung F; Bavli S; Solomon HS; Passan D; Dluhy R
    Medicine (Baltimore); 1979 Mar; 58(2):115-27. PubMed ID: 431398
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin II, plasma renin and sodium depletion as determinants of blood pressure response to saralasin in essential hypertension.
    Thananopavarn C; Golub MS; Eggena P; Barrett JD; Sambhi MP
    Circulation; 1980 May; 61(5):920-4. PubMed ID: 6988103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immediate pressor response to saralasin in man: a test of angiotensin II receptor vacancy.
    Wallace JM; Case DB; Laragh JH; Keim HJ; Drayer JI; Sealey JE
    Circ Res; 1979 Jan; 44(1):38-44. PubMed ID: 214254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the biological effects of two angiotensin II analogues in hypertensive patients with sodium depletion.
    Hata T; Ogihara T; Mikami H; Nakamaru M; Maruyama A; Mandai T; Kumahara Y
    Life Sci; 1978 Jun; 22(21):1955-62. PubMed ID: 672437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.